Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clarithromycin/clofazimine/rifabutin - RedHill Biopharma

Next Previous
Drug Profile

Clarithromycin/clofazimine/rifabutin - RedHill Biopharma

Alternative Names: Clarithromycin/rifabutin/clofazimine; Clofazimine/clarithromycin/rifabutin; Clofazimine/rifabutin/clarithromycin; Myoconda®; RHB 204; RHB-104; Rifabutin/clarithromycin/clofazimine; Rifabutin/clofazimine/clarithromycin

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centre for Digestive Diseases
  • Developer RedHill Biopharma
  • Class Anti-inflammatories; Antibacterials; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Aza compounds; Ethers; Macrolides; Phenazines; Piperidines; Rifamycins; Skin disorder therapies; Small molecules; Spiro compounds
  • Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections; Crohn's disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Crohn's disease; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
  • No development reported Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus
  • Discontinued Multiple sclerosis

Most Recent Events

  • 12 Mar 2025 RedHill Biopharma has patent protection for Clarithromycin/clofazimine/rifabutin in USA
  • 12 Mar 2025 RedHill Biopharma anticipates the US FDA guidance on regulatory path of RHB 204 in the second quarter of 2025
  • 12 Mar 2025 RedHill Biopharma plans a phase II trial for Crohn's disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top